DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
CAR t therapy aims to snuff out hidden lymphoma cells
Disease control Recruiting nowThis study tests whether a personalized cell therapy called liso-cel can stop large B-cell lymphoma from returning in patients who still have traces of cancer DNA after initial treatment. About 50 adults who are in remission but test positive for lymphoma DNA will receive their o…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
One-Shot gene therapy could simplify cancer treatment
Disease control Recruiting nowThis early-phase trial tests a new injection called IASO207 for people with relapsed or refractory B-cell blood cancers. Unlike current CAR-T therapies that require removing and engineering cells in a lab, IASO207 is designed to create cancer-fighting T cells directly inside the …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: EARLY_PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat lymphoma: Three-Drug combo enters human testing
Disease control Recruiting nowThis early-phase trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) in about 30 adults whose diffuse large B-cell lymphoma has returned or not responded to prior treatment. The main goal is to find the safest dose and check for side ef…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New 'Double Punch' CAR T-Cell therapy takes on tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called GF-CART01 for people with certain B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two cancer markers (CD…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New 'In-Body' CAR-T therapy takes aim at Hard-to-Treat lymphoma
Disease control Recruiting nowThis early study tests a new treatment called KSVCBD for people with a type of blood cancer called B-cell non-Hodgkin's lymphoma that has come back or not responded to other treatments. KSVCBD is a special therapy that works inside the body to help immune cells attack cancer cell…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to supercharge CAR T-Cells against tough lymphoma
Disease control Recruiting nowThis early-phase trial tests whether adding a drug called NT-I7 after standard CAR T-cell therapy can help the immune cells work better and last longer in people with relapsed or refractory large B-cell lymphoma. About 24 participants will receive NT-I7 after their CAR T treatmen…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Recruiting nowThis phase 2 trial tests whether adding epcoritamab, a bispecific antibody that helps the immune system attack cancer cells, to standard chemotherapy (EPOCH-R) is safe and effective for aggressive B-cell non-Hodgkin lymphoma. About 18 patients with hard-to-treat forms of the dise…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail aims to knock out tough lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New immune therapy shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial is testing a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard treatment. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will measure …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug offers hope for lymphoma patients who Can't get transplants
Disease control Recruiting nowThis phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see ho…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New Dual-Target CAR-T therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new treatment called C-CAR039 (Prizlon-cel) for people with large B-cell lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The goal is to find the saf…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New CAR-T therapy aims to tackle tough lymphoma
Disease control Recruiting nowThis early-stage study is testing a new immune cell therapy called CT1190B CAR-T in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New gene therapy combo tackles aggressive lymphoma in early trial
Disease control Recruiting nowThis early-stage study is testing a new gene therapy called UB-VV400, alone and with the drug rapamycin, in 70 adults with relapsed or refractory large B-cell lymphoma. The main goals are to find safe doses and check for side effects. Researchers will also look for signs that the…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:45 UTC
-
New 'Two-Pronged' CAR-T attack shows promise for tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 26, 2026 14:38 UTC
-
Blood test may let some lymphoma patients skip late chemo rounds
Knowledge-focused Recruiting nowThis study is testing whether a new blood test (PhasED-seq) can detect leftover cancer DNA in real time during standard chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL). For patients whose blood shows no cancer DNA halfway through treatment, doctors will sho…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: NA • Sponsor: Hua-Jay J Cherng, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC